<?xml version="1.0" encoding="UTF-8"?>
<p>This was an open‐label, phase 2, multicenter study of glasdegib in combination with cytarabine/daunorubicin in patients with previously untreated AML or high‐risk MDS. The study was conducted globally at 25 centers. The study was approved by an institutional review board or independent ethics committee at each study center, and was conducted in accordance with the study protocol, International Ethical Guidelines for Biomedical Research Involving Human Subjects (2002), Guidelines for Good Clinical Practice (1996), the Declaration of Helsinki (1996 and 2008), and applicable local regulatory requirements and laws. All patients provided written informed consent. The study is registered on 
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">http://clinicaltrials.gov</ext-link> (NCT01546038; Pfizer study number B1371003).
</p>
